US Broker Ratings

Oric Pharmaceuticals (ORIC) Stock Analysis: Exploring a 157% Upside Potential in the Biotech Arena

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical-stage biopharmaceutical company based out of South San Francisco, is gaining attention in the biotechnology sector for its innovative approach to tackling cancer resistance..

Inventiva S.A. (IVA): Biotech Stock with a 265% Potential Upside – An Investor’s Outlook

Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company based in Daix, France, is catching the attention of investors with its ambitious pipeline and strong analyst ratings. Specializing in the development of..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 76% Potential Upside in CNS Therapeutics

Rapport Therapeutics, Inc. (RAPP), a burgeoning player in the biotechnology sector, is catching the eye of investors with its promise of significant upside potential. Based in Boston, Massachusetts, this clinical-stage..

Personalis, Inc. (PSNL) Investor Outlook: Unpacking the 38.80% Potential Upside in Cancer Genomics

For investors with a keen interest in the healthcare sector, particularly within the diagnostics and research arena, Personalis, Inc. (NASDAQ: PSNL) presents a compelling opportunity. Situated at the intersection of..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unveiling a 46.94% Potential Upside for Investors

Theravance Biopharma, Inc. (NASDAQ: TBPH) presents an intriguing opportunity for investors seeking exposure to the biotechnology sector. With a market capitalization of $921.22 million, this U.S.-based company is committed to..

MBX Biosciences, Inc. (MBX) Stock Analysis: Unveiling a Potential 104% Upside for Investors

MBX Biosciences, Inc. (MBX) is drawing significant attention from the investment community with its impressive potential upside of 104.48%. As a clinical-stage biopharmaceutical company based in Carmel, Indiana, MBX is..

Zevra Therapeutics, Inc. (ZVRA): A Promising Biotech with 178% Potential Upside and Strong Analyst Confidence

Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a dynamic player in the biotechnology sector, is capturing investor attention with its remarkable growth potential and strong analyst confidence. Headquartered in Celebration, Florida, Zevra..

Kamada Ltd. (KMDA) Stock Analysis: Unpacking a 111% Potential Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA) is garnering significant attention from investors, particularly due to its impressive potential upside of 111.22%. As a key player in the healthcare sector, Kamada specializes in..

Definitive Healthcare Corp. (DH) Stock Report: Evaluating a 45% Potential Upside Amidst Sector Challenges

Definitive Healthcare Corp. (NASDAQ: DH), a prominent player in the healthcare information services industry, offers a compelling yet complex investment opportunity. With a market cap of $268.54 million, the company’s..

Tilray Brands, Inc. (TLRY) Stock Analysis: Potential Upside Amidst Healthcare Sector Challenges

Tilray Brands, Inc. (NASDAQ: TLRY) presents a fascinating case for investors, especially those interested in the dynamic healthcare sector. As a key player in the Drug Manufacturers – Specialty &..

Cullinan Therapeutics (CGEM): An Investor Outlook with a Potential 191% Upside

Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, is turning heads in the biotechnology sector with a promising pipeline of therapies for autoimmune diseases and..

Celcuity Inc. (CELC) Stock Analysis: Exploring a Potential 11% Upside in Biotechnology

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company, has captured investor attention with its promising pipeline and recent financial metrics suggesting a potential upside of 11.44%. As the healthcare sector..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: A 29.45% Upside Amidst Biotech Challenges

Ginkgo Bioworks Holdings, Inc. (DNA), a prominent player in the biotechnology industry, stands at a pivotal point for investors as it navigates the complexities of its market with potential upside...

Surmodics, Inc. (SRDX) Stock Report: Navigating Healthcare Innovation Amidst Financial Challenges

Surmodics, Inc. (SRDX) is at the forefront of innovation in the healthcare sector, specifically within the medical devices industry. Headquartered in Eden Prairie, Minnesota, this company is renowned for its..

Precigen, Inc. (PGEN) Stock Analysis: Exploring a 103.84% Upside Potential in the Booming Biotech Sector

Precigen, Inc. (NASDAQ: PGEN), a cutting-edge biotechnology company based in Germantown, Maryland, has been gaining attention in the healthcare sector with its innovative approach to gene and cell therapies. The..

Abivax SA (ABVX): Investor Outlook Reveals 27.89% Potential Upside Amid Robust Buy Ratings

For investors with an eye on the biotechnology sector, Abivax SA (ABVX) presents an intriguing opportunity. With a market capitalization of $8.96 billion, this Paris-based clinical-stage biotechnology company is focused..

Septerna, Inc. (SEPN) Investor Outlook: A Biotech Gem with Over 9% Upside

Septerna, Inc. (NASDAQ: SEPN) is capturing investor attention with its significant market cap of $1.23 billion and a promising potential upside of 9.66%. Operating in the biotechnology sector, Septerna is..

Tourmaline Bio, Inc. (TRML) Stock Analysis: A Biotech Contender with a Breakthrough Focus

Tourmaline Bio, Inc. (TRML), a biotechnology company at the forefront of developing treatments for autoimmune and inflammatory diseases, has recently captured investor attention. Despite its relatively nascent stage, the company’s..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: 47% Potential Upside Sparks Investor Interest

Organogenesis Holdings Inc. (NASDAQ: ORGO) is capturing investor attention with a noteworthy 47.31% potential upside, as indicated by the average target price set by analysts. This regenerative medicine company, headquartered..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Strong Buy with 75% Upside Potential

Oruka Therapeutics, Inc. (NASDAQ: ORKA) has captured the attention of investors in the biotechnology sector with its promising pipeline of novel monoclonal antibody therapeutics targeting psoriasis and other inflammatory conditions...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds